Look for a real prescription process
For a prescription drug, the September 26, 2026 federal rule requires an order from a licensed practitioner before it is dispensed. A service skipping that step raises a warning sign on FDA’s checklist.
Ask who makes the prescribing decision and when you can speak with that person. A treatment selection menu does not explain the assessment behind it.
FDA’s September 2026 warning covers products sold for human use despite labels such as “not for human consumption” or, on other products, “for research purposes.” The agency urges consumers to avoid them because it does not know their quality and they could be harmful.
Check the claim behind the badge
Calling a compounded preparation FDA-approved is false. FDA’s September 2026 guidance also rejects claims that a compounded drug has been checked for safety and whether it works when it has not. A claim that studies prove it gives the same results as an approved drug is also misleading.
Ask for the pharmacy’s actual name, then match it with the state record. An attractive website cannot answer that question for you.
FDA has found false semaglutide and tirzepatide labels using invented pharmacy names. Other false labels borrowed a real pharmacy’s name even though it had not prepared the medicine.
If the answers remain vague, keep your questions open and compare another licensed care route. A deadline on a promotional page need not become your decision deadline.
A useful next question
How can I check the pharmacy and the parcel?